Lina Kolloch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lina Kolloch has a total of 139 co-authors. Here are the top co-authors by number of shared publications:
- Christoph Schliemann
Medizinische Klinik A, Universitätsklinikum Münster, Münster, Germany
4 shared publications Georg Lenz
Department of Medicine A - Hematology, Hemostaseology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany
4 shared publicationsJan-Henrik Mikesch
Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany
4 shared publications- Julian Ronnacker
Department of Medicine A, University Hospital Münster, Münster, Germany
4 shared publications - Philipp Berning
Department of Medicine A, University Hospital Münster, Münster, Germany
4 shared publications - Andrew F. Berdel
Department of Medicine A, University Hospital Münster, Münster, Germany
3 shared publications
Latest Publications
- 24 November 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (22) , 7751-7766
Loncastuximab tesirine in heavily pretreated patients with large B-cell lymphoma: a German Lymphoma Alliance analysis
Few treatment options remain for patients with large B-cell lymphoma progressing after multiple lines of therapy, including the new CD19-directed antibody-drug conjugate loncastuximab tesirine (lonca). To further elucidate its efficacy and safety, we conducted a real-world analysis including data from 31 German centers. Ninety-three heavily pretreated patients received lonca in the third and later lines of therapy. Seventy-six percent had received treatment with chimeric antigen receptor T cells (n = 55), bispecific antibodies (n = 56), or both (n = 40). The overall response rate was 27%, and complete response rate was 10%. Median progression-free survival (mPFS) and median overall survival (mOS) were 2.2 and 4.4 months, respectively. The mPFS of responders was 11.4 months. Toxicity was acceptable, with grade ≥3 infections (in 13% of patients) being the most common adverse event. Patients receiving subsequent allogeneic stem cell transplantation survived significantly longer than the remaining nonconsolidated patients (mOS: 15.2 vs 3.8 months; P = .048). In multivariable analysis, no response to the last therapy before lonca (OS: hazard ratio [HR], 2.5; P = .014) and secondary International Prognostic Index (PFS/OS: HR, ≥2.0; P ≤ .024) were significantly associated with poor outcomes. Lonca demonstrated a favorable safety profile with moderate efficacy in heavily pretreated patients. Along with enabling timely access to subsequent therapy, efficacy in earlier lines with combination partners may further increase response rates and durability of response.
- 24 November 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (22) , 7751-7766
Loncastuximab tesirine in heavily pretreated patients with large B-cell lymphoma: a German Lymphoma Alliance analysis
Few treatment options remain for patients with large B-cell lymphoma progressing after multiple lines of therapy, including the new CD19-directed antibody-drug conjugate loncastuximab tesirine (lonca). To further elucidate its efficacy and safety, we conducted a real-world analysis including data from 31 German centers. Ninety-three heavily pretreated patients received lonca in the third and later lines of therapy. Seventy-six percent had received treatment with chimeric antigen receptor T cells (n = 55), bispecific antibodies (n = 56), or both (n = 40). The overall response rate was 27%, and complete response rate was 10%. Median progression-free survival (mPFS) and median overall survival (mOS) were 2.2 and 4.4 months, respectively. The mPFS of responders was 11.4 months. Toxicity was acceptable, with grade ≥3 infections (in 13% of patients) being the most common adverse event. Patients receiving subsequent allogeneic stem cell transplantation survived significantly longer than the remaining nonconsolidated patients (mOS: 15.2 vs 3.8 months; P = .048). In multivariable analysis, no response to the last therapy before lonca (OS: hazard ratio [HR], 2.5; P = .014) and secondary International Prognostic Index (PFS/OS: HR, ≥2.0; P ≤ .024) were significantly associated with poor outcomes. Lonca demonstrated a favorable safety profile with moderate efficacy in heavily pretreated patients. Along with enabling timely access to subsequent therapy, efficacy in earlier lines with combination partners may further increase response rates and durability of response.
- Open Access
- 7 August 2026
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 26 (10) , 670-688.e2
In Search of Long-Term Disease Control: CAR T-Cell Therapy With Axicabtagene Ciloleucel or Allogeneic Hematopoietic Cell Transplantation Against Relapsed/Refractory Large B-Cell Lymphoma
- 7 August 2026
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 26 (10) , 670-688.e2
Open AccessIn Search of Long-Term Disease Control: CAR T-Cell Therapy With Axicabtagene Ciloleucel or Allogeneic Hematopoietic Cell Transplantation Against Relapsed/Refractory Large B-Cell Lymphoma
- Open Access
- 30 June 2026
- Published by Elsevier in SSRN Electronic Journal
In Quest of Long-term Disease Control CAR T-cell Therapy with Axicabtagene ciloleucel or Allogeneic Hematopoietic Cell Transplantation against Relapsed/Refractory Large B-cell Lymphoma
Background: Large B-cell lymphoma (LBCL) remains challenging in the relapsed/refractory (r/r) setting. CD19-directed chimeric antigen receptor (CAR) T-cell therapy has become the preferred cellular immunotherapy, whereas allogeneic hematopoietic cell transplantation (allo-HCT) remains a salvage option. Comparative real-world data are limited.Patients and Methods: We retrospectively analyzed 187 patients with r/r LBCL treated with either allo-HCT or axicabtagene ciloleucel (axi-cel) at a single center. Primary endpoints were progression-free survival (PFS) and overall survival (OS). Secondary endpoints included relapse incidence (RI), non-relapse mortality (NRM), and treatment-related toxicities. Propensity score matching (PSM) was performed to adjust for baseline differences.Results: Response rates and RI were comparable between groups. However, NRM was significantly higher after allo-HCT than after axi-cel (36% vs. 12%; p<0.001), mainly due to infections and graft-versus-host disease. Consequently, axi-cel was associated with superior 12-month PFS (50.1% vs. 33.8%) and OS (60.5% vs. 43.2%; both p<0.05). These findings were confirmed in third-line-or-later and PSM analyses. Primary refractoriness and poor performance status independently predicted inferior outcomes. In patients with chemorefractory disease before cellular therapy, axi-cel provided significantly improved survival, whereas outcomes were comparable in patients with chemosensitive disease.Conclusion: Axi-cel provided superior survival compared with allo-HCT in r/r LBCL, primarily owing to lower treatment-related mortality and improved disease control in patients with chemorefractory disease.
- 30 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessIn Quest of Long-term Disease Control CAR T-cell Therapy with Axicabtagene ciloleucel or Allogeneic Hematopoietic Cell Transplantation against Relapsed/Refractory Large B-cell Lymphoma
Background: Large B-cell lymphoma (LBCL) remains challenging in the relapsed/refractory (r/r) setting. CD19-directed chimeric antigen receptor (CAR) T-cell therapy has become the preferred cellular immunotherapy, whereas allogeneic hematopoietic cell transplantation (allo-HCT) remains a salvage option. Comparative real-world data are limited.Patients and Methods: We retrospectively analyzed 187 patients with r/r LBCL treated with either allo-HCT or axicabtagene ciloleucel (axi-cel) at a single center. Primary endpoints were progression-free survival (PFS) and overall survival (OS). Secondary endpoints included relapse incidence (RI), non-relapse mortality (NRM), and treatment-related toxicities. Propensity score matching (PSM) was performed to adjust for baseline differences.Results: Response rates and RI were comparable between groups. However, NRM was significantly higher after allo-HCT than after axi-cel (36% vs. 12%; p<0.001), mainly due to infections and graft-versus-host disease. Consequently, axi-cel was associated with superior 12-month PFS (50.1% vs. 33.8%) and OS (60.5% vs. 43.2%; both p<0.05). These findings were confirmed in third-line-or-later and PSM analyses. Primary refractoriness and poor performance status independently predicted inferior outcomes. In patients with chemorefractory disease before cellular therapy, axi-cel provided significantly improved survival, whereas outcomes were comparable in patients with chemosensitive disease.Conclusion: Axi-cel provided superior survival compared with allo-HCT in r/r LBCL, primarily owing to lower treatment-related mortality and improved disease control in patients with chemorefractory disease.
- Open Access
- 6 November 2025
- Published by Elsevier in Blood Neoplasia
- Vol. 3 (1) , 100181
Impact of European LeukemiaNet–guided postremission therapy on outcomes of patients with AML from 2010 to 2022
- 6 November 2025
- Published by Elsevier in Blood Neoplasia
- Vol. 3 (1) , 100181
Open AccessImpact of European LeukemiaNet–guided postremission therapy on outcomes of patients with AML from 2010 to 2022
- Open Access
- 22 August 2025
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 60 (11) , 1533-1536
Immune reconstitution in AML and MDS patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) with treosulfan- or TBI-based conditioning
- 22 August 2025
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 60 (11) , 1533-1536
Open AccessImmune reconstitution in AML and MDS patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) with treosulfan- or TBI-based conditioning
- Open Access
- 3 July 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (9) , 2266-2269
Induction chemotherapy with CPX-351 in acute myeloid leukemia: revisiting the role of early bone marrow assessment
- 3 July 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (9) , 2266-2269
Open AccessInduction chemotherapy with CPX-351 in acute myeloid leukemia: revisiting the role of early bone marrow assessment
- 24 April 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (17) , 1943-1956
Common hereditary variants of the APOE gene and posttransplant outcome in acute myeloid leukemia
Apolipoprotein E (APOE) has multiple functions in metabolism and immunoregulation. Its common germ line variants APOE2, APOE3, and APOE4 give rise to 3 functionally distinct gene products. Previous studies reported yin-yang roles of APOE2 and APOE4 in immunological processes, but their effects in hematopoietic stem cell transplantation (HSCT) have never been studied. We performed APOE genotyping in 2 contemporary cohorts of 348 and 447 patients with acute myeloid leukemia who had received allogeneic HSCT and evaluated the associations of recipient and donor APOE genetic variations with posttransplant outcomes. Patients who carried at least 1 APOE2 allele had a higher risk of posttransplant death than APOE4 carriers in the discovery (hazard ratio [HR], 2.09; P = .024) and validation cohorts (HR, 1.96; P = .040). Detrimental APOE2 effects were driven by an increased risk of severe chronic graft-versus-host disease (GVHD; adjusted HR [HRadj], 1.85; P = .034) and nonrelapse death (HRadj, 1.72; P = .044). In non-APOE2 recipients, transplantation of an APOE2-positive allograft was associated with an increased incidence of grade 3 to 4 acute GVHD (HRadj, 2.82; P = .012) and severe chronic GVHD (HRadj, 2.54; P = .022) compared with APOE2-negative grafts. In summary, the APOE2 allele, typically considered a longevity gene in the general population, was associated with a higher risk of acute GVHD (HRadj, 2.75; P = .002), chronic GVHD (HRadj, 2.57; P = .001), and posttransplant mortality (HRadj, 1.79; P = .004), when present in either the host or transplanted from the donor.
- 24 April 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (17) , 1943-1956
Common hereditary variants of the APOE gene and posttransplant outcome in acute myeloid leukemia
Apolipoprotein E (APOE) has multiple functions in metabolism and immunoregulation. Its common germ line variants APOE2, APOE3, and APOE4 give rise to 3 functionally distinct gene products. Previous studies reported yin-yang roles of APOE2 and APOE4 in immunological processes, but their effects in hematopoietic stem cell transplantation (HSCT) have never been studied. We performed APOE genotyping in 2 contemporary cohorts of 348 and 447 patients with acute myeloid leukemia who had received allogeneic HSCT and evaluated the associations of recipient and donor APOE genetic variations with posttransplant outcomes. Patients who carried at least 1 APOE2 allele had a higher risk of posttransplant death than APOE4 carriers in the discovery (hazard ratio [HR], 2.09; P = .024) and validation cohorts (HR, 1.96; P = .040). Detrimental APOE2 effects were driven by an increased risk of severe chronic graft-versus-host disease (GVHD; adjusted HR [HRadj], 1.85; P = .034) and nonrelapse death (HRadj, 1.72; P = .044). In non-APOE2 recipients, transplantation of an APOE2-positive allograft was associated with an increased incidence of grade 3 to 4 acute GVHD (HRadj, 2.82; P = .012) and severe chronic GVHD (HRadj, 2.54; P = .022) compared with APOE2-negative grafts. In summary, the APOE2 allele, typically considered a longevity gene in the general population, was associated with a higher risk of acute GVHD (HRadj, 2.75; P = .002), chronic GVHD (HRadj, 2.57; P = .001), and posttransplant mortality (HRadj, 1.79; P = .004), when present in either the host or transplanted from the donor.